Your browser doesn't support javascript.
loading
Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma.
Bylund, Carma L; Eggly, Susan; LeBlanc, Thomas W; Kurtin, Sandra; Gandee, Marianne; Medhekar, Rohan; Fu, Alan; Khurana, Monica; Delaney, Kara; Divita, Alecia; McNamara, Michelle; Baile, Walter F.
Afiliação
  • Bylund CL; Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, USA.
  • Eggly S; Wayne State University Department of Oncology/Karmanos Cancer Institute, Detroit, MI, USA.
  • LeBlanc TW; Duke Cancer Institute, Durham, NC, USA.
  • Kurtin S; Division of Hematological Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Gandee M; University of Arizona and Arizona Cancer Center, Tucson, AZ, USA.
  • Medhekar R; Association of Community Cancer Centers, Rockville, MD, USA.
  • Fu A; Research and Development, Amgen Inc., Thousand Oaks, CA, USA.
  • Khurana M; Research and Development, Amgen Inc., Thousand Oaks, CA, USA.
  • Delaney K; Research and Development, Amgen Inc., Thousand Oaks, CA, USA.
  • Divita A; Adelphi Group, Doylestown, PA, USA.
  • McNamara M; Adelphi Group, Doylestown, PA, USA.
  • Baile WF; Adelphi Group, Doylestown, PA, USA.
Transl Behav Med ; 13(4): 255-267, 2023 04 15.
Article em En | MEDLINE | ID: mdl-36688466
Shared decision-making (SDM) is an important facet of patient-centered healthcare. Multiple myeloma (MM) is a cancer of the bone marrow that can return (relapse) after treatment. SDM may be especially pertinent for relapsed MM as there is no uniform standard of care and treatment selection can be complex. Few studies have examined the extent and relevance of SDM and patient-centered communication (PCC) in this relapsed and/or refractory (RRMM) setting. We conducted online surveys of 200 patients who had received 1­3 previous therapies and 200 physicians to compare treatment decision-making patterns in RRMM in the USA. Both physicians and patients felt that extending patient survival was a top treatment goal, regardless of the number of prior relapses. A lower percentage of physicians believed patients preferred a shared approach to treatment decision-making than patients who reported preferring such a shared role. Twice as many physicians than patients recalled ≥3 treatment options presented at first relapse. In conclusion, while improving survival was an important treatment goal for physicians and patients, there are discrepancies in physician and patient perceptions during RRMM treatment decision-making. Thus, communication tools are needed to facilitate SDM and PCC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Médicos / Oncologistas / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Médicos / Oncologistas / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article